Literature DB >> 17200488

More severe disability of North Africans vs Europeans with multiple sclerosis in France.

M Debouverie1, C Lebrun, S Jeannin, S Pittion-Vouyovitch, T Roederer, H Vespignani.   

Abstract

OBJECTIVE: To compare the clinical disease progression in European (E) and North African (NA) patients with multiple sclerosis (MS) patients in France.
METHODS: We compared the clinical features of MS in 211 NA patients and 2,945 E patients in a French population-based cohort with definite MS according to McDonald's criteria.
RESULTS: Among the NA patients with MS, 66.4% were women vs 72.9% of the E patients (p = 0.04), 15.6% had a primary progressive form of MS vs 11.7% of the E patients (p = 0.08), and the mean age at onset was 29.9 +/- 9.8 years in the NA patients vs 32.9 +/- 10.6 years in the E patients (p < 0.0001). In the NA patients, there was a higher proportion of patients with incomplete recovery from the first relapse (p < 0.0001), a shorter time between the first two relapses (p = 0.02), a higher number of relapses in the first 5 years (p = 0.03), and a shorter time to reach an Expanded Disability Status Scale score of 4.0 (p = 0.001) or 6.0 (p < 0.0001). The only statistical difference in these factors between NA patients born in France and those born in North Africa was the mean age at onset of symptoms: it was earlier in NA patients born in France (p < 0.0001).
CONCLUSIONS: The course of multiple sclerosis is more aggressive in North African than in European patients.

Entities:  

Mesh:

Year:  2007        PMID: 17200488     DOI: 10.1212/01.wnl.0000250347.51674.d7

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  Place of birth,age of immigration,and disability in Hispanics with multiple sclerosis.

Authors:  Lilyana Amezcua; David V Conti; Lihua Liu; Karina Ledezma; Annette M Langer-Goulda
Journal:  Mult Scler Relat Disord       Date:  2015-01       Impact factor: 4.339

2.  Interleukin-17- and interleukin-22-secreting myelin-specific CD4(+) T cells resistant to corticoids are related with active brain lesions in multiple sclerosis patients.

Authors:  Ana Cristina Wing; Joana Hygino; Thais B Ferreira; Taissa M Kasahara; Priscila O Barros; Priscila M Sacramento; Regis M Andrade; Solange Camargo; Fernanda Rueda; Soniza V Alves-Leon; Claudia Cristina Vasconcelos; Regina Alvarenga; Cleonice A M Bento
Journal:  Immunology       Date:  2015-12-02       Impact factor: 7.397

3.  Response to interferon-Beta treatment in afro-caribbeans with multiple sclerosis.

Authors:  S Jeannin; R Deschamps; N Chausson; P Cabre
Journal:  Mult Scler Int       Date:  2011-05-23

4.  No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients.

Authors:  Madlyne Becker; Clotilde Latarche; Emilie Roman; Marc Debouverie; Catherine Malaplate-Armand; Francis Guillemin
Journal:  BMC Neurol       Date:  2015-05-13       Impact factor: 2.474

5.  Oligoclonal Bands in Cerebrospinal Fluid of Black Patients with Multiple Sclerosis.

Authors:  Paulo Diniz da Gama; Luís dos Ramos Machado; José Antonio Livramento; Hélio Rodrigues Gomes; Tarso Adoni; Rogério de Rizo Morales; Rodrigo Assad Diniz da Gama; Daniel Assad Diniz da Gama; Marco Aurélio Lana-Peixoto; Yara Dadalti Fragoso; Dagoberto Callegaro
Journal:  Biomed Res Int       Date:  2015-07-29       Impact factor: 3.411

6.  Differences in MS clinical and epidemiological characteristics between Ashkenazi and non-Ashkenazi Jewish patients in Israel: a retrospective single center study.

Authors:  Arnon Karni; Gil Ben Noon; Tamara Shiner; Ifat Vigiser; Hadar Kolb; Keren Regev
Journal:  Sci Rep       Date:  2022-03-16       Impact factor: 4.379

Review 7.  MS in self-identified Hispanic/Latino individuals living in the US.

Authors:  Lilyana Amezcua; Jorge R Oksenberg; Jacob L McCauley
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-09-25

8.  Generational changes in multiple sclerosis phenotype in North African immigrants in France: A population-based observational study.

Authors:  Clotilde Nardin; Clotilde Latarche; Marc Soudant; Camille Dahan; Maud Michaud; Sophie Pittion-Vouyovitch; Francis Guillemin; Marc Debouverie; Guillaume Mathey
Journal:  PLoS One       Date:  2018-03-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.